Plain-English translation of NCT07334431 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment approach for advanced stomach cancer that involves combining fruquintinib with two other established cancer medications. The study wants to see if this three-drug combination is both safe and effective as a first-line treatment (meaning the first treatment you receive) for patients whose stomach cancer has a specific marker called HER2. Researchers will watch for both how well the treatment works and what side effects patients experience.
Currently, treatment options for advanced HER2-positive stomach cancer are limited. Doctors hope that adding this new medication to existing treatments might help more patients respond better and live longer with fewer serious side effects.
You likely qualify if…
You likely don't qualify if…
As a participant, you would take fruquintinib as an oral medication combined with the other two cancer drugs (trastuzumab and XELOX), which are standard treatments for your type of cancer. You would visit the hospital regularly for blood tests, imaging scans, and check-ups so doctors can monitor how well the treatment is working and watch for any side effects. The study will track your health and cancer response over time to determine if this combination is safe and effective.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China